Nurix Therapeutics, Inc. (NRIX)
25.30
-0.52
(-2.03%)
USD |
NASDAQ |
Sep 03, 16:00
25.30
0.00 (0.00%)
After-Hours: 20:00
Nurix Therapeutics Cash from Investing (Quarterly) : 93.00M for May 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | 93.00M |
| February 28, 2026 | -123.83M |
| November 30, 2025 | 0.346M |
| August 31, 2025 | 50.48M |
| May 31, 2025 | 71.50M |
| February 28, 2025 | 25.53M |
| November 30, 2024 | -140.82M |
| August 31, 2024 | -21.34M |
| May 31, 2024 | -131.07M |
| February 29, 2024 | 35.51M |
| November 30, 2023 | -14.37M |
| August 31, 2023 | 22.78M |
| May 31, 2023 | 43.83M |
| February 28, 2023 | 16.07M |
| November 30, 2022 | 55.01M |
| Date | Value |
|---|---|
| August 31, 2022 | -63.08M |
| May 31, 2022 | -4.765M |
| February 28, 2022 | 40.03M |
| November 30, 2021 | -36.52M |
| August 31, 2021 | -12.23M |
| May 31, 2021 | -57.11M |
| February 28, 2021 | -2.387M |
| November 30, 2020 | -124.56M |
| August 31, 2020 | -108.08M |
| May 31, 2020 | -2.336M |
| February 29, 2020 | -19.42M |
| November 30, 2019 | -4.365M |
| August 31, 2019 | 3.507M |
| May 31, 2019 | 9.955M |
| February 28, 2019 | -0.599M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Monte Rosa Therapeutics, Inc. | -28.86M |
| Gilead Sciences, Inc. | -10.35B |
| TG Therapeutics, Inc. | 1.03M |
| Cue Biopharma, Inc. | 0.00 |
| Keros Therapeutics, Inc. | -0.155M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -96.57M |
| Cash from Financing (Quarterly) | 0.066M |
| Free Cash Flow | -304.53M |
| Free Cash Flow Per Share (Quarterly) | -0.8868 |
| Free Cash Flow to Equity (Quarterly) | -98.00M |
| Free Cash Flow to Firm (Quarterly) | -98.51M |
| Free Cash Flow Yield | -12.03% |